Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Yale University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01566370CT.gov Zonisamide for Heavy Drinkers With Bipolar Disorder | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Alcohol-Related Disorders
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Zonisamide (this asset) | Yale University | P2 | CCC · 53 |
| Naltrexone | Boston Medical Center | P4 | BB |
| Gabapentin | Boston Medical Center | P2 | B |
| Tirzepatide | South West Sydney Local Health District | P2 | CCC |
| Teonanacatl | Centre for Addiction and Mental Health | P2 | CCC |
| Pemvidutide | Altimmune, Inc. | P2 | CCC |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | South West Sydney Local Health District | P1/2 | CCC |
| Ethylicum | The University of Texas Health Science Center at San Antonio | N/A | D |
| Citalopram | University of Washington | N/A | D |
+11 more in the Alcohol-Related Disorders cohort
Other indications for Zonisamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P4 | BBB · 74 |
| Epilepsy | — | P4 | BB · 69 |
| Migraine Disorder | — | P4 | B · 63 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Zonisamide in Alcohol-Related Disorders. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/zonisamide-alcohol-related-disorders
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →